The FDA on May 14, 2019 approved BAVENCIO® (Avelumab) in combination with INLYTA® (Axitinib) for first-line treatment of patients with advanced Renal Cell Carcinoma (RCC). BAVENCIO® is a product of EMD Serono, Inc. and INLYTA® is a product of Pfizer, Inc.
Bottom Ad
Advertisement
Subscribe
